...
首页> 外文期刊>Expert opinion on drug delivery >Optimization of novel tocopheryl acetate nanoemulsions for parenteral delivery of curcumin for therapeutic intervention of sepsis
【24h】

Optimization of novel tocopheryl acetate nanoemulsions for parenteral delivery of curcumin for therapeutic intervention of sepsis

机译:新型醋酸生育酚乙酸酯纳米乳剂用于姜黄素胃肠外给药治疗脓毒症的优化

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective: The objective of this study is to develop a nanostructured parenteral delivery system, laden with curcumin (CUR), for the therapeutic intervention of sepsis and associated pathologies.Methods: Nanoemulsions were fabricated using sonication and speed homogenization. Size and zeta potential were evaluated by dynamic light scattering and transmission electron microscopy analysis. Pharmacodynamic and pharmacokinetic studies were performed on a rat model of lipopolysaccharide (LPS)-induced sepsis.Results: The drug content of optimized nanoemulsion (F5) formulation (particle size 246 ± 08 nm, polydispersity index (PDI) of 0.120, zeta potential of-41.1 ± 1.2 mV) was found to be 1.25 mg/ml. In vitro release studies demonstrated that F5 was able to sustain the release of CUR for up to 24 h. Minimal hemolysis and cellular toxicity demonstrated its suitability for intravenous administration. Significant reduction of inflammatory mediator levels was mediated through enhanced uptake by in RAW 264.7 and THP-1 in absence/presence of LPS. Nanoemulsion resulted in an improvement of plasma concentration (AUCF5/AUC CUR = 8.80) and tissue distribution of CUR in rats leading to a reduction in LPS-induced lung and liver injury due to less neutrophil migration, reduced TNF-α levels and oxidative stress (demonstrated by levels of lipid peroxides as well as carbonylated proteins) as confirmed by histopathological studies.Conclusion: The findings suggest that the therapeutic performance (i.e., reduction in oxidative damage in tissues) of CUR can be enhanced by employing tocol acetate nanoemulsions (via improving pharmacokinetics and tissue distribution) as a platform for drug delivery in sepsis-induced organ injury.
机译:目的:本研究的目的是开发一种载有姜黄素(CUR)的纳米结构的肠胃外给药系统,用于脓毒症及其相关疾病的治疗性干预。方法:采用超声和速度均质法制备纳米乳剂。通过动态光散射和透射电子显微镜分析评估大小和ζ电势。在脂多糖(LPS)诱导的脓毒症大鼠模型上进行了药效学和药代动力学研究。结果:优化的纳米乳剂(F5)制剂的药物含量(粒径246±08 nm,多分散指数(PDI)为0.120,ζ电位为-41.1±1.2 mV)被发现为1.25 mg / ml。体外释放研究表明F5能够维持CUR释放长达24小时。最小的溶血和细胞毒性证明了其适合静脉内给药。在缺少/存在LPS的情况下,通过增加RAW 264.7和THP-1的摄取可以介导炎症介质水平的显着降低。纳米乳剂可改善大鼠血浆浓度(AUCF5 / AUC CUR = 8.80)和组织中CUR的分布,由于中性粒细胞迁移减少,TNF-α水平降低和氧化应激,LPS诱导的肺和肝损伤减少(组织病理学研究证实:脂质过氧化物和羰基化蛋白的水平得到证实。结论:研究结果表明,通过使用生育酚乙酸酯纳米乳剂可以改善CUR的治疗性能(即减少组织的氧化损伤)(通过改善药代动力学和组织分布)作为败血症诱导的器官损伤中药物输送的平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号